Amgen/$AMGN
Amgen stock plummets after Novartis reported its investigational Lp(a) drug pelacarsen failed to reduce cardiovascular events in Phase III, stoking concerns over Amgen’s competing olpasiran and prompting a BMO Capital downgrade.
2 hours agoLightyear AI
1D1W1MYTD1Y5YMAX
Capital at risk
About Amgen
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis, which has been further strengthened with the launch of new drugs in blood cancers (Blincyto) and solid tumors (Imdelltra). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
- Ticker
- $AMGN
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 31,500
- Headquarters
- Thousand Oaks, United States
- Website
- www.amgen.com
Amgen Metrics
BasicAdvanced
$236B
27.17
$16.09
0.41
$9.80
2.31%
Price and volume
Market cap
$236B
Beta
0.41
52-week high
$447.03
52-week low
$269.77
Average daily volume
2.5M
Dividend rate
$9.80
Financial strength
Current ratio
1.371
Quick ratio
0.95
Long term debt to equity
443.694
Total debt to equity
490.281
Dividend payout ratio (TTM)
58.61%
Interest coverage (TTM)
4.23%
Profitability
EBITDA (TTM)
17,569
Gross margin (TTM)
71.89%
Net profit margin (TTM)
22.95%
Operating margin (TTM)
33.40%
Effective tax rate (TTM)
15.01%
Revenue per employee (TTM)
$1,210,000
Management effectiveness
Return on assets (TTM)
8.67%
Return on equity (TTM)
91.47%
Valuation
Price to earnings (TTM)
27.166
Price to revenue (TTM)
6.186
Price to book
20.22
Price to tangible book (TTM)
-8.61
Price to free cash flow (TTM)
23.161
Free cash flow yield (TTM)
4.32%
Free cash flow per share (TTM)
18.878
Dividend yield (TTM)
2.24%
Forward dividend yield
2.31%
Growth
Revenue change (TTM)
9.10%
Earnings per share change (TTM)
31.60%
3-year revenue growth (CAGR)
12.74%
10-year revenue growth (CAGR)
5.42%
3-year earnings per share growth (CAGR)
2.72%
10-year earnings per share growth (CAGR)
5.12%
3-year dividend per share growth (CAGR)
6.38%
10-year dividend per share growth (CAGR)
10.59%
What the Analysts think about Amgen
Analyst ratings (Buy, Hold, Sell) for Amgen stock.
Analyst projections of the future price of Amgen stock.
Bulls say / Bears say
Amgen delivered strong Q2 2026 execution: revenue rose 10% to $10.1 billion, product sales increased 9%, 22 products posted double-digit growth, and free cash flow reached $3.5 billion. (Amgen)
Repatha is showing substantial momentum, with Q2 sales up 37% year over year to $953 million; recent VESALIUS-CV data also showed a 31% relative reduction in major cardiovascular events in a high-risk diabetic subgroup, supporting potential for broader use. (Amgen)
The pipeline offers meaningful long-term optionality: MariTide has multiple Phase 3 obesity studies underway, including quarterly-dosing and diabetes programs, while Imdelltra received European approval and subcutaneous Tepezza generated positive Phase 3 topline results. (SEC)
Prolia sales fell 32% year over year to $759 million in Q2 2026, while Xgeva declined 34% to $352 million; Amgen said multiple biosimilars have launched globally and more are expected, pointing to continuing erosion in a major franchise. (Amgen)
Pricing and volume pressure is broadening beyond bone health: Otezla sales fell 21% and Enbrel sales fell 4% in Q2 2026, with Enbrel’s net selling price down 22% partly due to Medicare Part D price setting and higher 340B mix. (Amgen)
Amgen remains highly leveraged, reporting $5.4 billion of current debt and $51.9 billion of long-term debt as of June 30, 2026; net interest expense was $1.33 billion in the first half, limiting financial flexibility for further acquisitions or shareholder returns. (SEC)
Data summarised monthly by Lightyear AI. Last updated on 8 Sept 2026.
Amgen Financial Performance
Revenues and expenses
Amgen Earnings Performance
Company profitability
Upcoming events
Amgen News
AllArticlesVideos
Disappointing Clinical Trial Results Are Dragging Novartis, Amgen and the Dow Lower Tuesday
Investopedia2 hours ago
Tuesday's First Moves: BE Joining SPX, AMGN & NVS Fall, PANW Downgrade
Schwab Network3 hours ago
Intel, Amgen, Novartis, Bloom Energy, and More Stocks That Explain Today's Market
Barrons6 hours ago
Funds containing Amgen
AllUSDGBPEUR
Fund name | Fund size | $AMGN weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 8.57% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 8.57% |
iShares Dow Jones Industrial Average€EXI3 | €315M | 4.85% |
iShares S&P 500 Health Care Sector€IUHE | €125M | 3.51% |
iShares MSCI World Health Care Sector Advanced€CBUF | €606M | 2.14% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.